Please ensure Javascript is enabled for purposes of website accessibility

Why Bausch Health Jumped More Than 12% Today

By Howard Smith – Oct 8, 2020 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company delivered preliminary third-quarter numbers, and investors liked what they heard.

What happened

Shares of Bausch Health Companies (BHC -2.51%) were up by 12.6% as of 1 p.m. EDT Thursday after the company released preliminary results for the third quarter. The full report is scheduled to be released on Nov. 3. 

So what

The healthcare products and pharmaceutical company said it expects to report third-quarter revenue of at least $2.1 billion. This would amount to a 28% increase over second-quarter sales, though a 3% decline compared to Q3 2019. The midpoint of analysts' expectations for the just-completed period is just $1.98 billion. 

close-up of woman about to put contact lens in bright blue eye

Image source: Getty Images.

The company also said it forecasts full-year revenue of approximately $7.9 billion, which would also exceed analysts' current expectations. 

Now what

Bausch Health is basing its estimates on a continuation of the rate of recovery from impacts of the COVID-19 pandemic. Even after Thursday's jump, shares are down by about 40% year to date. 

The company said in August that it plans to spin off its Bausch + Lomb eye care business as a separate company. The eye health portion of the business represented slightly more than 40% of revenue in 2019. The company's other business units focus mainly on treatments for gastrointestinal diseases (Salix Pharmaceuticals) and dermatology medicines (Ortho Dermatologics). 

The company plans for the spinoff to occur in 2021 after certain conditions, approvals, and reporting reorganizations are complete. The state of the international recovery from the pandemic will be key to the company's performance, as more than half of Bausch + Lomb's sales are outside the United States.

Howard Smith has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$7.39 (-2.51%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.